Addex Therapeutics Ltd ADXN
Annual
Quarterly
No annual revenue total was found in Addex Therapeutics Ltd's SEC filings.
Addex Therapeutics Ltd (ADXN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
147.83M
+15.2% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADXN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Geneva, Switzerland
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1574232
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Oct 2, 2026 | Oct 2, 2026 |
| 6-K | Current report (foreign issuer) | Sep 28, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 25, 2026 | Sep 25, 2026 |
| 6-K | Current report (foreign issuer) | Aug 26, 2026 | Aug 26, 2026 |
All 279 Addex Therapeutics Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.